Comparison of pan-immune-inflammation with other inflammation markers of long-term survival after ST-segment elevation myocardial infarction.

Murat B., Murat S., Ozgeyik M., Bilgin M.

European journal of clinical investigation, vol.53, 2023 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 53
  • Publication Date: 2023
  • Doi Number: 10.1111/eci.13872
  • Journal Name: European journal of clinical investigation
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Keywords: neutrophil-to-lymphocyte ratio (NLR), pan- immune inflammation value (PIV), platelet-to-lymphocyte ratio (PLR), segment elevation myocardial infarction (ST), systemic immune-inflammation (SII), LYMPHOCYTE RATIO, INDEX PREDICTS, CARDIOVASCULAR-DISEASES, CLINICAL-OUTCOMES, CELL COUNT, IMPACT, ASSOCIATION, NEUTROPHIL, PROGNOSIS, MORTALITY
  • Eskisehir Osmangazi University Affiliated: Yes


Background Atherosclerosis is a process that causes coronary artery disease and is associated with the inflammatory response. In this study, we aimed to evaluate the association of Pan-Immune-Inflammation Value (PIV) with in-hospital and long-term mortality in STEMI patients. Methods A total of 658 patients who were admitted to the emergency department of two tertiary centers with the diagnosis of STEMI and underwent percutaneous coronary intervention (PCI) between 2018 and 2022 were retrospectively enrolled. PIV and other inflammation parameters were compared for the study population. The primary outcome was one-year all-cause of mortality. Results The mean age was 58.7 +/- 17.1 years and 507 (76.9%) were male. The mean duration of the follow-up was 18.8 +/- 8.5 months (median 18.9 months). PIV was superior to the neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and systemic immune-inflammation index for the prediction of primary and secondary outcomes in STEMI. Conclusion Our study reveals that PIV is a better predictor of mortality in STEMI patients. Prospective studies are needed to validate this biomarker.